Recorded fact · drug.trial_access

drug.trial_access for empagliflozin

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact ab0e426b resolves to.

The record

Fact id	`ab0e426b6d1a73f39080ec45`
Entity	drug: empagliflozin
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "EMPAGLIFLOZIN",
 "recruitingInterventionalCount": 94,
 "notYetRecruitingCount": 29,
 "byPhase": {
  "PHASE1/PHASE2": 4,
  "PHASE3": 18,
  "PHASE1": 7,
  "PHASE4": 29,
  "PHASE2": 18,
  "EARLY_PHASE1": 8,
  "NA": 6,
  "PHASE2/PHASE3": 4
 },
 "trials": [
  {
   "nctId": "NCT03424005",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2018-03-30",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "France",
    "Germany",
    "Israel",
    "South Korea",
    "Spain",
    "Taiwan",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03424005"
  },
  {
   "nctId": "NCT05972564",
   "briefTitle": "The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Vanderbilt University Medical Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2023-09-06",
   "conditions": [
    "Obesity",
    "Metabolic Syndrome"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05972564"
  },
  {
   "nctId": "NCT07038356",
   "briefTitle": "Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Christian Schulze",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2025-12-08",
   "conditions": [
    "Acute Decompensated Heart Failure (ADHF)"
   ],
   "countries": [
    "Germany"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07038356"
  },
  {
   "nctId": "NCT07845630",
   "briefTitle": "A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Boehringer Ingelheim",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-29",
   "startDate": "2026-10-14",
   "conditions": [
    "Healthy"
   ],
   "countries": [
    "Germany"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07845630"
  },
  {
   "nctId": "NCT06424288",
   "briefTitle": "A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Boehringer Ingelheim",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2024-06-17",
   "conditions": [
    "Heart Failure"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Belgium",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China",
    "Colombia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06424288"
  },
  {
   "nctId": "NCT06935370",
   "briefTitle": "A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Boehringer Ingelheim",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2025-05-20",
   "conditions": [
    "Heart Failure"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Belgium",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China",
    "Colombia",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06935370"
  },
  {
   "nctId": "NCT06249932",
   "briefTitle": "Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "National Taiwan University Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2024-03-13",
   "conditions": [
    "Heart Failure With Reduced Ejection Fraction",
    "End Stage Renal Disease on Dialysis"
   ],
   "countries": [
    "Taiwan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06249932"
  },
  {
   "nctId": "NCT07064473",
   "briefTitle": "EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Boehringer Ingelheim",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2025-07-22",
   "conditions": [
    "Diabetes Mellitus, Type 2",
    "Hypertension",
    "Cardiovascular Diseases"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Belgium",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07064473"
  },
  {
   "nctId": "NCT06653738",
   "briefTitle": "Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Insel Gruppe AG, University Hospital Bern",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-23",
   "startDate": "2026-07-02",
   "conditions": [
    "Kidney Stone",
    "Nephrolithiasis",
    "Dietary Exposure"
   ],
   "countries": [
    "France",
    "Germany",
    "Italy",
    "Switzerland"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06653738"
  },
  {
   "nctId": "NCT06483074",
   "briefTitle": "Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Chinese University of Hong Kong",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-2
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 49893446dc23b96fd08dae6a7420f11fba2a916f88f67953cfdd81ebdf58b80b.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.